Objective
to compare a personalised DAPT duration (3, 6, or 24 months) guided by the DAPT score with a standard duration of DAPT for 12 months after PCI
Study
randomised, open-label, superiority trial
Population
patients undergoing PCI to receive either a personalised or standard DAPT
Endpoints
net adverse clinical event (NACE) at 24 months (composite of all-cause death, myocardial infarction, stroke, urgent target vessel revascularisation or BARC type 2, 3, or 5 bleeding)
Conclusion
Among patients undergoing PCI, a personalised DAPT duration (3-24 months) based on a clinical risk score led to a lowered risk of NACE when compared to standard care (12 months of DAPT).
Piccolo et al. J Am Coll Cardiol. 2025 Dec 9.